… a public offering in October that will allow us to fund operations into 2022, well beyond the expected top-line … of $5.50 per share with full exercise of underwriters’ option to purchase 1,363,636 additional ordinary shares. Net … financial statements, the potential exercise of share options is not included in the diluted earnings per share …
… $15.75 per share including full exercise of underwriters’ option to purchase 862,500 additional ordinary shares. Gross … oligonucleotide QR-110 for treatment of inherited retinal dystrophy in adults and children with LCA10 ○ Structure-based computational approach for optimizing oligonucleotides for A-to-I editing Presented at …
… robust clinical proof of concept in the early phase of our development program. I also want to thank the patients that … LCA10 compound heterozygous patient cells and homozygous optic cups in a dose dependent manner. Based on this data, … into pre-clinical development for the treatment of dystrophic epidermolysis bullosa (DEB). QR-313 is an RNA …
… financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in …
… 10 patients. David M. Rodman, MD was appointed as Chief Development Strategy Officer of ProQR, and will lead the … 10 (LCA 10) patients. The trial, named PQ-110-001, is an open-label trial that will include approximately 6 children … 6 adults (≥ 18 years) that have LCA 10 due to one or two copies of the p.Cys998X mutation. During the trial, patients …
… the nasal potential difference (NPD). PQ-010-002 is an open label 28-day study of topical exposure of QR-010 in 16 CF patients, 8 homozygous (carrying two copies) for the ΔF508 mutation and 8 compound heterozygous …
… for QR-110 from the FDA. The planned Phase 1/2 open-label trial (PQ-110-001) will include approximately 6 … 6 adults (≥ 18 years) that have LCA 10 due to one or two copies of the p.Cys998X mutation. During the trial, patients … with expertise in genetic retinal disease in the US and Europe. The primary objective will be to assess safety and …
… financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in … Premium Equity settled Employee Benefit Reserve Option premium on convertible loan Translation Reserve …
… financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in … Equity settled Option Employee premium …
… ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results LEIDEN, The Netherlands & … financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in …